/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Sandhya Girish

Gilead Sciences (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

141

Papers

5.5K

Citations

33

h-index

71

i10-index

Sandhya Girish is an academic researcher from Gilead Sciences (United States). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Cancer Treatment and Pharmacology. The author has an h-index of 33, co-authored 120 publications.

ORCID: 0000-0002-9336-1600

Research Topics

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Cancer Treatment and Pharmacology Cancer Immunotherapy and Biomarkers Peptidase Inhibition and Analysis

Papers by this author

works

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 · Journal of Clinical Oncology · 758 citations

https://doi.org/10.1200/jco.2010.29.5865

Howard A. Burris Hope S. Rugo Svetislava J. Vukelja Charles L. Vogel

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

2010 · Journal of Clinical Oncology · 591 citations

https://doi.org/10.1200/jco.2009.26.2071

Ian E. Krop Muralidhar Beeram Shanu Modi Suzanne F. Jones

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

2012 · Journal of Clinical Oncology · 362 citations

https://doi.org/10.1200/jco.2011.40.5902

Ian E. Krop Patricia LoRusso Kathy D. Miller Shanu Modi

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

2012 · Cancer Chemotherapy and Pharmacology · 262 citations

https://doi.org/10.1007/s00280-011-1817-3

Sandhya Girish Manish Gupta Bei Wang Dan Lu

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

2014 · Clinical Cancer Research · 203 citations

https://doi.org/10.1158/1078-0432.ccr-14-2093

Hirdesh Uppal Estelle Doudement Kaushiki Mahapatra Walter C. Darbonne

A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

2012 · Cancer · 102 citations

https://doi.org/10.1002/cncr.27622

Muralidhar Beeram Ian E. Krop Howard A. Burris Sandhya Girish

Research topics

topics

HER2/EGFR in Cancer Research

Monoclonal and Polyclonal Antibodies Research

Cancer Treatment and Pharmacology

Cancer Immunotherapy and Biomarkers

Peptidase Inhibition and Analysis

Chat about Author

Papers

Chat

Click to start Chat